Accrued active pharmaceutical ingredient product price adjustment current.

No definition available.

Name:	fgen_AccruedActivePharmaceuticalIngredientProductPriceAdjustmentCurrent
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Accrued long term co promotion liability current.

+ References

No definition available.

+ Details

Name:	fgen_AccruedLongTermCoPromotionLiabilityCurrent
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Accrued long-term co-promotional liability non current.

+ References

No definition available.

+ Details

Name:	fgen_AccruedLongTermCoPromotionalLiabilityNonCurrent
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Number of regulatory milestones.

+ References

No definition available.

+ Details

Name:	fgen_NumberOfRegulatoryMilestones
Namespace Prefix:	fgen_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of pre-launch inventory capitalized of aggregate inventory balance.

+ References

No definition available.

+ Details

Name:	fgen_PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance
Namespace Prefix:	fgen_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Reversal of previously accrued long term co promotion expenses.

+ References

No definition available.

+ Details

Name:	fgen_ReversalOfPreviouslyAccruedLongTermCoPromotionExpenses
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

+ Details

Name:	us-gaap_Depreciation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount by which the fair value of an investment in debt and equity securities categorized as Available-for-sale is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.

+ References

No definition available.

+ Details

Name:	us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (g)(7)
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section 05
-Paragraph 5
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320

+ Details

Name:	us-gaap_Supplies
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Details

Name:	srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=fgen_UnitedStatesAndRestOfWorldMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=country_CN
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Balance Sheet Components - Additional Information (Detail)	3 Months Ended	12 Months Ended			36 Months Ended
	Sep. 30, 2020 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($) Milestone	Dec. 31, 2018 USD ($)	Dec. 31, 2020 USD ($)	Jun. 30, 2020 USD ($)
Schedule of Available-for-sale Securities [Line Items]
Other-than-temporary impairment loss					$ 0
Percentage of pre-launch inventory capitalized of aggregate inventory balance		29.00%			29.00%
Number of regulatory milestones \| Milestone			2
Unbilled contract assets		$ 2,147,000	$ 180,000,000		$ 2,147,000
Depreciation expense		11,678,000	11,147,000	$ 6,562,000
API product price change in estimated variable consideration		0	36,324,000		0
Accrued long term co promotion liability current		11,500,000			11,500,000
Profit share liability		6,547,000	490,000		6,547,000
Europe [Member]
Schedule of Available-for-sale Securities [Line Items]
Unbilled contract assets						$ 130,000,000.0
Astellas Agreement [Member] \| Europe [Member]
Schedule of Available-for-sale Securities [Line Items]
Unbilled contract assets			130,000,000.0
AstraZeneca Agreements [Member]
Schedule of Available-for-sale Securities [Line Items]
Unbilled contract assets			50,000,000.0
Accrued long-term co-promotional expenses			53,100,000
Reversal of previously accrued long-term co-promotion expenses	$ 84,400,000
AstraZeneca Agreements [Member] \| Other Noncurrent Liabilities
Schedule of Available-for-sale Securities [Line Items]
Accrued long-term co-promotional expenses		27,400,000			27,400,000
AstraZeneca Agreements [Member] \| U.S./RoW [Member]
Schedule of Available-for-sale Securities [Line Items]
Unbilled contract assets			$ 50,000,000.0
AstraZeneca Agreements [Member] \| China [Member]
Schedule of Available-for-sale Securities [Line Items]
Profit share liability		$ 7,000,000.0			$ 7,000,000.0